pretreatment resistance to hepatitis c virus protease inhibitors boceprevir/telaprevir in hepatitis c subgenotype 1a-infected patients from manitoba
Clicks: 191
ID: 213529
2013
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
30.0
/100
189 views
11 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
BACKGROUND: Traditional therapy with pegylated interferon and ribavirin combined with the new protease inhibitors boceprevir or telaprevir has demonstrated improved outcomes in hepatitis C virus (HCV)-infected patients. Prevalence data regarding pre-existing drug-resistant variants to these two new virus inhibitors in the Canadian population are not available.
| Reference Key |
andonov2013canadianpretreatment
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Anton Andonov;Kamran Kadkhoda;Carla Osiowy;Kelly Kaita |
| Journal | indian journal of pharmacology |
| Year | 2013 |
| DOI |
10.1155/2013/273856
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.